Lifeward: Buy Rating Reiterated as Partner-Led Growth Strategy Drives Momentum; 12-Month Price Target Maintained at $10
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Lifeward with a $10 price target, citing partner-led growth momentum. Q2 2026 revenue rose 16% YoY to $6.6M, driven by strong U.S. sales and double-digit growth in ReWalk and AlterG lines. The Ottobock Care pilot aims to expand access via 50 clinics, supporting capital-efficient revenue streams. Despite acknowledged risks, the analyst views the risk-reward profile as attractive, supported by robust balance sheet metrics including $11.2M in growth capital.
Lifeward, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $10.00 price target.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Swayampakula Ramakanth has given his Buy rating due to a combination of factors related to Lifeward’s operating momentum and business model. He highlights that second-quarter 2026 revenue rose 16% year over year to $6.6M, with U.S. sales climbing 33% and both ReWalk Personal Exoskeleton and AlterG product lines showing double-digit growth, supporting his view that the new commercial strategy is starting to drive a meaningful inflection in the top line.
Ramakanth’s rating is based on the potential of Lifeward’s partner-led distribution approach and the company’s valuation upside. The Ottobock Care pilot, which expands access to ReWalk through more than 50 U.S. clinics, is seen as a capital-efficient way to build a durable revenue stream, while Lifeward’s access to up to $11.2M in growth capital and pro forma net cash of about $6.5M underpin its balance sheet. Using a risk-adjusted NPV of future revenues and net cash, he maintains a 12‑month price target of $10, viewing the risk‑reward profile as attractive despite acknowledged commercial, partnership, regulatory, financial, and IP risks.